Advanced PET (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) Global Market (2010 -2015)
Global PET (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) Market
Propelled by the transparent reimbursement policies, new emerging economies, novel applications such as Alzheimer’s and continually expanding oncology application segment, the global positron emission tomography (PET) market is estimated to reach around $6.3 billion in 2010.
Reimbursement plays a major role in the adoption of any medical imaging technology. The approval of PET scanning reimbursement in the U.S. by the Medicare and Medicaid for the Alzheimer’s disease widened the opportunities for the major market participants. Currently there are approximately 4.7 million Alzheimer’s patients in the U.S. PET enables the radiologist to have the early diagnosis of the Alzheimer disease among the patients. Therefore, this would further increase the demand of the PET scanners among the various health care centers.
Similarly, single photon emission computed tomography (SPECT) scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape by opening up numerous lucrative opportunities in niche market such as neuroendocrine tumor imaging. Moreover, technological advancements such as attenuation correction and image acquisition/reconstruction tools have enhanced SPECT end users' confidence in its diagnostic and prognostic capabilities. The global PET SPECT market is expected to grow from an estimated $6.5 billion in 2010 to $10.3 billion in 2015, at an estimated CAGR of 9.4% from 2010 to 2015. The PET segment is estimated to account for the largest share – i.e. 75% – of the overall PET SPECT installations at 3,691 units in 2010. This segment is expected to reach 6,390 units in 2015, at a CAGR of 11.6% for the same period.
Oncology and cardiology are the most significant applications of the PET SPECT market. Oncology accounts for about 90% of the PET market, whereas, cardiology accounts for about 85% of SPECT application market. Neurological application of PET and SPECT is a niche market and is dependent on the development of appropriate radionuclides and tracers.
Scope of the report
This research report categorizes the global PET SPECT market on the basis of technology, application, and geography; forecasting revenues and analyzing trends in each of the following submarkets:
On the basis of technology:
Stand alone PET, PET/CT, stand alone SPECT and SPECT/CT
On the basis of application:
Oncology, non small cell lung cancer, Hodgkin and non Hodgkin lymphoma, head and neck cancer, colorectal cancer, breast cancer; cardiology and neurology
On the basis of geography:
U.S., EMEA (Europe, Middle East and Africa), Asia-Pacific and Rest of the world
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.
What makes our reports unique?
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.
Key questions answered
Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.
Propelled by the transparent reimbursement policies, new emerging economies, novel applications such as Alzheimer’s and continually expanding oncology application segment, the global positron emission tomography (PET) market is estimated to reach around $6.3 billion in 2010.
Reimbursement plays a major role in the adoption of any medical imaging technology. The approval of PET scanning reimbursement in the U.S. by the Medicare and Medicaid for the Alzheimer’s disease widened the opportunities for the major market participants. Currently there are approximately 4.7 million Alzheimer’s patients in the U.S. PET enables the radiologist to have the early diagnosis of the Alzheimer disease among the patients. Therefore, this would further increase the demand of the PET scanners among the various health care centers.
Similarly, single photon emission computed tomography (SPECT) scanners have been on the forefront to bring about significant changes in the diagnostic imaging equipment landscape by opening up numerous lucrative opportunities in niche market such as neuroendocrine tumor imaging. Moreover, technological advancements such as attenuation correction and image acquisition/reconstruction tools have enhanced SPECT end users' confidence in its diagnostic and prognostic capabilities. The global PET SPECT market is expected to grow from an estimated $6.5 billion in 2010 to $10.3 billion in 2015, at an estimated CAGR of 9.4% from 2010 to 2015. The PET segment is estimated to account for the largest share – i.e. 75% – of the overall PET SPECT installations at 3,691 units in 2010. This segment is expected to reach 6,390 units in 2015, at a CAGR of 11.6% for the same period.
Oncology and cardiology are the most significant applications of the PET SPECT market. Oncology accounts for about 90% of the PET market, whereas, cardiology accounts for about 85% of SPECT application market. Neurological application of PET and SPECT is a niche market and is dependent on the development of appropriate radionuclides and tracers.
Scope of the report
This research report categorizes the global PET SPECT market on the basis of technology, application, and geography; forecasting revenues and analyzing trends in each of the following submarkets:
On the basis of technology:
Stand alone PET, PET/CT, stand alone SPECT and SPECT/CT
On the basis of application:
Oncology, non small cell lung cancer, Hodgkin and non Hodgkin lymphoma, head and neck cancer, colorectal cancer, breast cancer; cardiology and neurology
On the basis of geography:
U.S., EMEA (Europe, Middle East and Africa), Asia-Pacific and Rest of the world
Each section will provide market data, market drivers, trends and opportunities, top-selling products, key players, and competitive outlook. This report will also provide market tables for covering the sub-segments and micro-markets. In addition, the report also provides more than 20 company profiles covering all the sub-segments.
What makes our reports unique?
- We provide the longest market segmentation chain in this industry- not many reports provide market breakdown upto level 5.
- We provide 10% customization. Normally it is seen that clients do not find specific market intelligence that they are looking for. Our customization will ensure that you necessarily get the market intelligence you are looking for and we get a loyal customer.
- We conduct detailed market positioning, product positioning and competitive positioning. Entry strategies, gaps and opportunities are identified for all the stakeholders.
- Comprehensive market analysis for the following sectors:
Pharmaceuticals, Medical Devices, Biotechnology, Semiconductor and Electronics, Energy and Power Supplies, Food and Beverages, Chemicals, Advanced Materials, Industrial Automation, and Telecom and IT. We also analyze retailers and super-retailers, technology providers, and research and development (R&D) companies.
Key questions answered
- Which are the high-growth segments/cash cows and how is the market segmented in terms of applications and materials?
- What are market estimates and forecasts; which markets are doing well and which are not?
- Where are the gaps and opportunities; what is driving the market?
- Which are the key playing fields? Which are the winning edge imperatives?
- How is the competitive outlook; who are the main players in each of the segments; what are the key selling products; what are their strategic directives, operational strengths and product pipelines? Who is doing what?
Powerful Research and analysis
The analysts working with MarketsandMarkets come from renowned publishers and market research firms, globally, adding their expertise and domain understanding. We get the facts from over 22,000 news and information sources, a huge database of key industry participants and draw on our relationships with more than 900 market research companies across the world. We, at MarketsandMarkets, are inspired to help our clients grow by providing qualitative business insights with our huge market intelligence repository.
EXECUTIVE SUMMARY
1 INTRODUCTION
1.1 Key take-aways
1.2 Report description
1.3 Markets covered
1.4 Stakeholders
1.5 Research methodology
2 SUMMARY
3 MARKET OVERVIEW
3.1 Introduction
3.1.1 Evolution of PET technology
3.1.1.1 Challenges in early stages
3.1.1.2 Concerted efforts to resolve concerns of infrastructure & finance
3.1.1.2.1 Facilities’ to purchase patient-specific doses
3.1.1.2.2 Limited financial risk for hospitals
3.1.2 Learning Curve Of PET
3.2 Emerging therapeutic uses of PET
3.3 Hybrid imaging edges past stand-alone modules
3.4 Non-linear fusion capability – a new opportunity in hybrid imaging
3.4.1 Advantages of non-linear software-based system
3.5 Comparison of U.S. & Europe in PET/CT installations
3.5.1 End User profile – hospitals command maximum PET/CT installations in both geographies
3.6 Decreasing impact of stand alone pet in oncology in U.S.
3.7 Emerging markets for PET
3.8 Low-cost production centers to lower price-tag
3.8.1 GE healthcare focus is on India
3.8.2 Positron corporation’s – production center in China
3.8.3 Siemens healthcare – tapping market potential in emerging countries
3.9 Winning imperatives – different for PET and SPECT
3.10 Market share analysis – GE and Siemens lead the field
3.11 Ancillary products markets of PET
3.11.1 Radionuclides used in PET – FDG most used drug
3.11.2 Scintillation detectors – BGO the most preferred
3.12 Competitive landscape
3.13 Factors influencing market growth
3.13.1 Demand side drivers
3.13.2 Supply side drivers
3.13.3 Threats
3.13.4 Opportunities
3.13.5 Key competitive points
3.14 Patent growth analysis
4 PET SPECT MARKET BY TECHNOLOGY
4.1 PET
4.1.1 Drivers
4.1.1.1 PET for cancer management
4.1.1.2 Increasing aging population
4.1.1.3 Enhanced reimbursement scenario for PET in U.S.
4.1.1.4 Ready availability of radiopharmaceuticals from cyclotrons
4.1.2 Prohibition of self-referral is a restraint
4.1.3 Stand alone PET
4.1.3.1 Cardiac operations – opportunity for stand alone PET
4.1.3.2 Restraints
4.1.3.2.1 Dominance of hybrid PET/CT leads to decline in demand for stand-alone PET
4.1.3.2.2 Availability of refurbished hybrid systems dampens demand for new stand-alone PET scanners
4.1.4 PET/CT
4.1.4.1 Drivers and opportunities
4.1.4.1.1 Continuous improvement in PET/CT product Lines support growth in revenue
4.1.4.1.2 PET/CT plays an important role in treatment planning
4.1.4.1.3 Decreased market barriers to entry stimulates PET/CT sales
4.1.4.2 High price tag prohibits sales to end users
4.1.5 PET/MRI
4.1.5.1 Potential clinical applications
4.1.5.2 Superior imaging compared to CT in neurological studies
4.1.5.3 Clinical PET/MRI in Boston – steps by Siemens and Philips
4.2 Difference between PET and SPECT
4.3 SPECT
4.3.1 Stand-alone SPECT
4.3.1.1 Drivers
4.3.1.1.1 SPECT helps from detection to evaluation of treatment of neurological diseases
4.3.1.1.2 Helps in improved treatment for cardio-vascular diseases using SPECT
4.3.1.1.3 Low cost radionuclides help SPECT to gain an edge over PET
4.3.1.2 Low spatial resolution & absence of anatomical data
4.3.2 SPECT/CT
4.3.2.1 Drivers
4.3.2.1.1 Advanced technology increases confidence in SPECT/CT
4.3.2.1.2 Opportunity in niche application drives growth
4.3.2.2 Restraints
4.3.2.3 Availability of novel imaging agents is crucial
4.3.2.4 Technologist training is important
5 PET SPECT APPLICATION MARKET
5.1 PET SPECT applications
5.1.1 Oncology
5.1.1.1 Non-small-cell lung cancer
5.1.1.2 Hodgkin and non-hodgkin lymphoma
5.1.1.3 Colorectal cancer
5.1.1.4 Breast cancer
5.1.1.5 Head and neck cancer
5.1.2 Cardiology
5.1.3 Neurology
6 GEOGRAPHIC ANALYSIS
6.1 U.S. PET SPECT market
6.2 EMEA PET SPECT market
6.3 APAC PET SPECT market
7 COMPETITIVE LANDSCAPE
7.1 Competitive scenario
7.2 Competitive structure
7.3 PET commands significantly more competitive development
8 COMPANY PROFILES
8.1 AGFA-GEVAERT N.V.
8.1.1 Overview
8.1.2 Primary business
8.1.3 Strategy
8.1.4 Developments
8.2 ALOKA CO. LTD.
8.2.1 Overview
8.2.2 Primary business
8.2.3 Strategy
8.2.4 Developments
8.3 CARDIARC LTD.
8.3.1 Overview
8.3.2 Primary business
8.3.3 Strategy
8.3.4 Developments
8.4 COVIDIEN PLC.
8.4.1 Overview
8.4.2 Primary business
8.4.3 Strategy
8.4.4 Developments
8.5 DIGIRAD CORPORATION
8.5.1 Overview
8.5.2 Primary business
8.5.3 Strategy
8.5.4 Developments
8.6 ESAOTE S.P.A.
8.6.1 Overview
8.6.2 Primary business
8.6.3 Strategy
8.6.4 Developments
8.7 GAMMA MEDICA IDEAS INC.
8.7.1 Overview
8.7.2 Primary business
8.7.3 Developments
8.8 GE HEALTHCARE
8.8.1 Overview
8.8.2 Primary business
8.8.3 Strategy
8.8.4 Developments
8.9 HOLOGIC INC.
8.9.1 Overview
8.9.2 Primary business
8.9.3 Strategy
8.9.4 Developments
8.10 MEDX, INC.
8.10.1 Overview
8.10.2 Primary business
8.10.3 Strategy
8.10.4 Developments
8.11 MERGE HEALTHCARE, INC.
8.11.1 Overview
8.11.2 Primary business
8.11.3 Strategy
8.11.4 Developments
8.12 NAVISCAN, INC.
8.12.1 Overview
8.12.2 Primary business
8.12.3 Strategy
8.12.4 Developments
8.13 PHILIPS ELECTRONICS
8.13.1 Overview
8.13.2 Primary business
8.13.3 Strategy
8.13.4 Developments
8.14 POSITRON CORPORATION
8.14.1 Overview
8.14.2 Primary business
8.14.3 Strategy
8.14.4 Developments
8.15 SEGAMI CORPORATION
8.15.1 Overview
8.15.2 Primary business
8.15.3 Strategy
8.15.4 Developments
8.16 SIEMENS HEALTHCARE
8.16.1 Overview
8.16.2 Primary business
8.16.3 Strategy
8.16.4 Developments
8.17 SPECTRUM DYNAMICS LTD.
8.17.1 Overview
8.17.2 Primary business
8.17.3 Strategy
8.17.4 Developments
APPENDIX
U.S. Patents
EUROPE Patents
JAPAN Patents
1 INTRODUCTION
1.1 Key take-aways
1.2 Report description
1.3 Markets covered
1.4 Stakeholders
1.5 Research methodology
2 SUMMARY
3 MARKET OVERVIEW
3.1 Introduction
3.1.1 Evolution of PET technology
3.1.1.1 Challenges in early stages
3.1.1.2 Concerted efforts to resolve concerns of infrastructure & finance
3.1.1.2.1 Facilities’ to purchase patient-specific doses
3.1.1.2.2 Limited financial risk for hospitals
3.1.2 Learning Curve Of PET
3.2 Emerging therapeutic uses of PET
3.3 Hybrid imaging edges past stand-alone modules
3.4 Non-linear fusion capability – a new opportunity in hybrid imaging
3.4.1 Advantages of non-linear software-based system
3.5 Comparison of U.S. & Europe in PET/CT installations
3.5.1 End User profile – hospitals command maximum PET/CT installations in both geographies
3.6 Decreasing impact of stand alone pet in oncology in U.S.
3.7 Emerging markets for PET
3.8 Low-cost production centers to lower price-tag
3.8.1 GE healthcare focus is on India
3.8.2 Positron corporation’s – production center in China
3.8.3 Siemens healthcare – tapping market potential in emerging countries
3.9 Winning imperatives – different for PET and SPECT
3.10 Market share analysis – GE and Siemens lead the field
3.11 Ancillary products markets of PET
3.11.1 Radionuclides used in PET – FDG most used drug
3.11.2 Scintillation detectors – BGO the most preferred
3.12 Competitive landscape
3.13 Factors influencing market growth
3.13.1 Demand side drivers
3.13.2 Supply side drivers
3.13.3 Threats
3.13.4 Opportunities
3.13.5 Key competitive points
3.14 Patent growth analysis
4 PET SPECT MARKET BY TECHNOLOGY
4.1 PET
4.1.1 Drivers
4.1.1.1 PET for cancer management
4.1.1.2 Increasing aging population
4.1.1.3 Enhanced reimbursement scenario for PET in U.S.
4.1.1.4 Ready availability of radiopharmaceuticals from cyclotrons
4.1.2 Prohibition of self-referral is a restraint
4.1.3 Stand alone PET
4.1.3.1 Cardiac operations – opportunity for stand alone PET
4.1.3.2 Restraints
4.1.3.2.1 Dominance of hybrid PET/CT leads to decline in demand for stand-alone PET
4.1.3.2.2 Availability of refurbished hybrid systems dampens demand for new stand-alone PET scanners
4.1.4 PET/CT
4.1.4.1 Drivers and opportunities
4.1.4.1.1 Continuous improvement in PET/CT product Lines support growth in revenue
4.1.4.1.2 PET/CT plays an important role in treatment planning
4.1.4.1.3 Decreased market barriers to entry stimulates PET/CT sales
4.1.4.2 High price tag prohibits sales to end users
4.1.5 PET/MRI
4.1.5.1 Potential clinical applications
4.1.5.2 Superior imaging compared to CT in neurological studies
4.1.5.3 Clinical PET/MRI in Boston – steps by Siemens and Philips
4.2 Difference between PET and SPECT
4.3 SPECT
4.3.1 Stand-alone SPECT
4.3.1.1 Drivers
4.3.1.1.1 SPECT helps from detection to evaluation of treatment of neurological diseases
4.3.1.1.2 Helps in improved treatment for cardio-vascular diseases using SPECT
4.3.1.1.3 Low cost radionuclides help SPECT to gain an edge over PET
4.3.1.2 Low spatial resolution & absence of anatomical data
4.3.2 SPECT/CT
4.3.2.1 Drivers
4.3.2.1.1 Advanced technology increases confidence in SPECT/CT
4.3.2.1.2 Opportunity in niche application drives growth
4.3.2.2 Restraints
4.3.2.3 Availability of novel imaging agents is crucial
4.3.2.4 Technologist training is important
5 PET SPECT APPLICATION MARKET
5.1 PET SPECT applications
5.1.1 Oncology
5.1.1.1 Non-small-cell lung cancer
5.1.1.2 Hodgkin and non-hodgkin lymphoma
5.1.1.3 Colorectal cancer
5.1.1.4 Breast cancer
5.1.1.5 Head and neck cancer
5.1.2 Cardiology
5.1.3 Neurology
6 GEOGRAPHIC ANALYSIS
6.1 U.S. PET SPECT market
6.2 EMEA PET SPECT market
6.3 APAC PET SPECT market
7 COMPETITIVE LANDSCAPE
7.1 Competitive scenario
7.2 Competitive structure
7.3 PET commands significantly more competitive development
8 COMPANY PROFILES
8.1 AGFA-GEVAERT N.V.
8.1.1 Overview
8.1.2 Primary business
8.1.3 Strategy
8.1.4 Developments
8.2 ALOKA CO. LTD.
8.2.1 Overview
8.2.2 Primary business
8.2.3 Strategy
8.2.4 Developments
8.3 CARDIARC LTD.
8.3.1 Overview
8.3.2 Primary business
8.3.3 Strategy
8.3.4 Developments
8.4 COVIDIEN PLC.
8.4.1 Overview
8.4.2 Primary business
8.4.3 Strategy
8.4.4 Developments
8.5 DIGIRAD CORPORATION
8.5.1 Overview
8.5.2 Primary business
8.5.3 Strategy
8.5.4 Developments
8.6 ESAOTE S.P.A.
8.6.1 Overview
8.6.2 Primary business
8.6.3 Strategy
8.6.4 Developments
8.7 GAMMA MEDICA IDEAS INC.
8.7.1 Overview
8.7.2 Primary business
8.7.3 Developments
8.8 GE HEALTHCARE
8.8.1 Overview
8.8.2 Primary business
8.8.3 Strategy
8.8.4 Developments
8.9 HOLOGIC INC.
8.9.1 Overview
8.9.2 Primary business
8.9.3 Strategy
8.9.4 Developments
8.10 MEDX, INC.
8.10.1 Overview
8.10.2 Primary business
8.10.3 Strategy
8.10.4 Developments
8.11 MERGE HEALTHCARE, INC.
8.11.1 Overview
8.11.2 Primary business
8.11.3 Strategy
8.11.4 Developments
8.12 NAVISCAN, INC.
8.12.1 Overview
8.12.2 Primary business
8.12.3 Strategy
8.12.4 Developments
8.13 PHILIPS ELECTRONICS
8.13.1 Overview
8.13.2 Primary business
8.13.3 Strategy
8.13.4 Developments
8.14 POSITRON CORPORATION
8.14.1 Overview
8.14.2 Primary business
8.14.3 Strategy
8.14.4 Developments
8.15 SEGAMI CORPORATION
8.15.1 Overview
8.15.2 Primary business
8.15.3 Strategy
8.15.4 Developments
8.16 SIEMENS HEALTHCARE
8.16.1 Overview
8.16.2 Primary business
8.16.3 Strategy
8.16.4 Developments
8.17 SPECTRUM DYNAMICS LTD.
8.17.1 Overview
8.17.2 Primary business
8.17.3 Strategy
8.17.4 Developments
APPENDIX
U.S. Patents
EUROPE Patents
JAPAN Patents
LIST OF TABLES
1 Global PET Spect market, by revenues 2008 – 2015 ($Million)
2 Global PET SPECT installations, by products 2008 – 2015 (No. of units)
3 Type of image fusion
4 Company-wise investment in PET mostly directed to India
5 Winning imperatives for PET and SPECT market
6 Radionuclides used in PET imaging
7 Detector material used in PET imaging
8 Global PET market, by products 2008 – 2015 ($Million)
9 Global PET market, by geography 2008 – 2015 ($Million)
10 Global PET installations, by products 2008 – 2015 (No. of units)
11 Global PET installations, by geography 2008 – 2015 (No. of units)
12 Global stand alone PET market, by geography 2008 – 2015 ($Million)
13 Global stand alone PET installations, by geography 2008 – 2015 (No. of units)
14 Global PET/CT market, by geography 2008 – 2015 ($Million)
15 Global PET/CT installations, by geography 2008 – 2015 (No. of units)
16 Global SPECT market, by products 2008 – 2015 ($Million)
17 Global SPECT market, by geography 2008 – 2015 ($Million)
18 Global SPECT installations, by products 2008 – 2015 (No. of units)
19 Global SPECT installations, by geography 2008 – 2015 (No. of units)
20 Global stand alone SPECT market, by geography 2008 – 2015 ($Million)
21 Global stand alone SPECT installations, by geography 2008 – 2015 (No. of units)
22 Global SPECT/CT market, by geography 2008 – 2015 ($Million)
23 Global SPECT/CT installations, by geography 2008 – 2015 (No. of units)
24 Global PET SPECT market, by applications 2008 – 2015 ($Million)
25 Global oncology market, by applications 2008 – 2015 ($Million)
26 Global non-small-cell lung cancer market, by geography 2008 – 2015 ($Million)
27 Global hodgkin and non-hodgkin lymphoma market, by geography 2008 – 2015 ($Million)
28 Global colorectal cancer market, by geography 2008 – 2015 ($Million)
29 Global breast cancer market, by geography 2008 – 2015 ($Million)
30 Global head and neck cancer market, by geography 2008 – 2015 ($Million)
31 Global cardiology market, by geography 2008 – 2015 ($Million)
32 Global neurology market, by geography 2008 – 2015 ($Million)
33 Global PET SPECT market, by geography 2008 – 2015 ($Million)
34 Global PET SPECT installations, by geography 2008 – 2015 (No. of units)
35 U.S. PET SPECT market, by products 2008 – 2015 ($Million)
36 U.S. PET SPECT installations, by products 2008 – 2015 (No. of units)
37 Emea PET SPECT market, by products 2008 – 2015 ($Million)
38 EMEA PET SPECT installations, by products 2008 – 2015 (No. of units)
39 APAC PET SPECT market, by products 2008 – 2015 ($Million)
40 APAC PET SPECT installations, by products 2008 – 2015 (No. of units)
41 Mergers and acquisitions (June 2008 – August 2009)
42 Agreements, Collaborations, joint ventures (April 2008 – August 2010)
43 New product launches (January 2008 – March 2010)
44 Services and developments (June 2008 – June 2010)
1 Global PET Spect market, by revenues 2008 – 2015 ($Million)
2 Global PET SPECT installations, by products 2008 – 2015 (No. of units)
3 Type of image fusion
4 Company-wise investment in PET mostly directed to India
5 Winning imperatives for PET and SPECT market
6 Radionuclides used in PET imaging
7 Detector material used in PET imaging
8 Global PET market, by products 2008 – 2015 ($Million)
9 Global PET market, by geography 2008 – 2015 ($Million)
10 Global PET installations, by products 2008 – 2015 (No. of units)
11 Global PET installations, by geography 2008 – 2015 (No. of units)
12 Global stand alone PET market, by geography 2008 – 2015 ($Million)
13 Global stand alone PET installations, by geography 2008 – 2015 (No. of units)
14 Global PET/CT market, by geography 2008 – 2015 ($Million)
15 Global PET/CT installations, by geography 2008 – 2015 (No. of units)
16 Global SPECT market, by products 2008 – 2015 ($Million)
17 Global SPECT market, by geography 2008 – 2015 ($Million)
18 Global SPECT installations, by products 2008 – 2015 (No. of units)
19 Global SPECT installations, by geography 2008 – 2015 (No. of units)
20 Global stand alone SPECT market, by geography 2008 – 2015 ($Million)
21 Global stand alone SPECT installations, by geography 2008 – 2015 (No. of units)
22 Global SPECT/CT market, by geography 2008 – 2015 ($Million)
23 Global SPECT/CT installations, by geography 2008 – 2015 (No. of units)
24 Global PET SPECT market, by applications 2008 – 2015 ($Million)
25 Global oncology market, by applications 2008 – 2015 ($Million)
26 Global non-small-cell lung cancer market, by geography 2008 – 2015 ($Million)
27 Global hodgkin and non-hodgkin lymphoma market, by geography 2008 – 2015 ($Million)
28 Global colorectal cancer market, by geography 2008 – 2015 ($Million)
29 Global breast cancer market, by geography 2008 – 2015 ($Million)
30 Global head and neck cancer market, by geography 2008 – 2015 ($Million)
31 Global cardiology market, by geography 2008 – 2015 ($Million)
32 Global neurology market, by geography 2008 – 2015 ($Million)
33 Global PET SPECT market, by geography 2008 – 2015 ($Million)
34 Global PET SPECT installations, by geography 2008 – 2015 (No. of units)
35 U.S. PET SPECT market, by products 2008 – 2015 ($Million)
36 U.S. PET SPECT installations, by products 2008 – 2015 (No. of units)
37 Emea PET SPECT market, by products 2008 – 2015 ($Million)
38 EMEA PET SPECT installations, by products 2008 – 2015 (No. of units)
39 APAC PET SPECT market, by products 2008 – 2015 ($Million)
40 APAC PET SPECT installations, by products 2008 – 2015 (No. of units)
41 Mergers and acquisitions (June 2008 – August 2009)
42 Agreements, Collaborations, joint ventures (April 2008 – August 2010)
43 New product launches (January 2008 – March 2010)
44 Services and developments (June 2008 – June 2010)
LIST OF FIGURES
1 PET application market share in 2009
2 Evolution of PET
3 Emerging therapeutic uses of PET
4 U.S. leads Europe in installations in 2009
5 Hospitals have more PET/CT installed than non-hospitals
6 Pet and PET/CT utilization in oncology in U.S.
7 Relative evaluation of emerging countries in market competitiveness
8 India, favored site for investment since 2008
9 Global PET SPECT market analysis (Units Installed) 2009
10 Global PET market analysis (units installed) 2009
11 Global SPECT market analysis (units installed) 2009
12 Competitive landscape of PET and SPECT market
13 Driving factor analysis of PET SPECT market
14 Patents by assignee (2005 – 2010)
15 Patent analysis, by geography (2005 – 2010)
16 Patents by products (2005 – 2010)
17 YOY patent analysis (2005 – 2010)
18 Potential clinical applications of PET/MRI
19 Difference between PET and SPECT
20 Competitive scenario of leading players in PET and SPECT, 2008 – 2010
21 Strategic developments (January 2008 – June 2010)
22 Comparison of competitive development between PET and SPECT
1 PET application market share in 2009
2 Evolution of PET
3 Emerging therapeutic uses of PET
4 U.S. leads Europe in installations in 2009
5 Hospitals have more PET/CT installed than non-hospitals
6 Pet and PET/CT utilization in oncology in U.S.
7 Relative evaluation of emerging countries in market competitiveness
8 India, favored site for investment since 2008
9 Global PET SPECT market analysis (Units Installed) 2009
10 Global PET market analysis (units installed) 2009
11 Global SPECT market analysis (units installed) 2009
12 Competitive landscape of PET and SPECT market
13 Driving factor analysis of PET SPECT market
14 Patents by assignee (2005 – 2010)
15 Patent analysis, by geography (2005 – 2010)
16 Patents by products (2005 – 2010)
17 YOY patent analysis (2005 – 2010)
18 Potential clinical applications of PET/MRI
19 Difference between PET and SPECT
20 Competitive scenario of leading players in PET and SPECT, 2008 – 2010
21 Strategic developments (January 2008 – June 2010)
22 Comparison of competitive development between PET and SPECT
